Trial · NCT05650229
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in-patient-reported fatigue symptoms and impacts on daily living measured by Patient-Reported Outcomes Measurement Information System (PROMIS®) Fatigue PMD Short Form | Baseline and 48 Weeks | Change in t-score. Higher scores indicate greater fatigue severity. |
| Primary | Change in 30 Second Site-to-Stand Test. | Baseline and 48 Weeks | Change in number of stands |
| Secondary | Change in Quality of Life in Neurological Disorders (Neuro-QoL) Lower Extremity Function (Mobility) Short Form | Baseline and 48 weeks | Change in t-score. Higher scores indicate greater functional ability. |
| Secondary | Change in Individual Activity Assessments - Interference | Baseline and 48 Weeks | Assessing how much Primary Mitochondrial Disease symptoms get in the way of the ability to perform individually selected activities. A 5 point scale ranging from "No interference" to "Completely interferes" |
| Secondary | Individual Activity Assessment - Change | 48 weeks | Assessing the ability to perform individually selected activities compared to baseline. A 5 point scale ranging from "Much worse" to "Much better" |
| Secondary | Change in Patient Global Impression of Severity | Baseline and 48 weeks | Scale ranging from 1 (none) to 4 (severe). |
| Secondary | Score on Patient Global Impression of Change | 48 weeks | Scale ranging from 2 (much better) to -2 (much worse). |
| Secondary | Change in Clinician Global Impression of Severity | Baseline and 48 weeks | Scale ranging from 1 (none) to 4 (severe). |
| Secondary | Score on Clinician Global Impression of Change | 48 weeks | Scale ranging from 2 (much better) to -2 (much worse). |
| Secondary | Change in Newcastle Mitochondrial Disease Adult Scale (NMDAS) - subscales I-III | Baseline and 48 weeks | Measured on a 6-point rating scale from 0 to 5. Total score across all 3 subscales ranges from 0 to 140. Higher scores indicate more extensive and severe system involvements. |
| Secondary | Change from baseline in Glycated haemoglobin (HbA1c) for subjects with diabetes | Baseline and 48 weeks | mmol/mol |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05650229/registered